Ivosidenib in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome (R/R MDS): Updated enrollment and results of a phase 1 dose-escalation and expansion substudy Meeting Abstract
| Authors: | Sallman, D. A.; Foran, J. M.; Watts, J. M.; Stein, E.; De Botton, S.; Fathi, A. T.; Prince, G. T.; Stone, R. M.; Patel, P. A.; Roboz, G. J.; Arellano, M. L.; Erba, H. P.; Pigneux, A.; Baratam, P.; Thomas, X. G.; Bai, X.; Kapsalis, S. M.; Garcia-Manero, G.; Dinardo, C. D. |
| Abstract Title: | Ivosidenib in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome (R/R MDS): Updated enrollment and results of a phase 1 dose-escalation and expansion substudy |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680301954 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.7053 |
| Notes: | Meeting Abstract: 7053 -- Meeting also held virtually -- Source: Wos |
